MaxCyte Inc (LSE:MXCT) - Overview

Stock Report

MaxCyte Inc MXCT

Last Price
GBX135.50

Day Change
0.00|0.00%

As of 06/12/2016
11:28:24 GMT | GBX
Minimum 15 Minutes Delay.

Last Close135.50p
Day Range135.00 - 135.00
Mkt Cap58.95Mil
52-Wk Range75.00 - 137.00
Yield %0.00
ISINUS57777K1060
Volume30,000
P/E-25.00
P/S9.39
P/CF-478.80

Share Price

Total Returns 07/12/2016

 Chg (%)  
More ...
MaxCyte Inc6.27 
FTSE 100 TR GBP1.82
 
Financials
201320142015
More ...
Income Statement
Turnover4.134.606.27
Operating Profit-0.49-0.82-0.51
Net Profit-0.58-1.18-0.98
Reported EPS-3.99-5.53-5.47
Balance Sheet
Current Assets1.413.824.18
Non Current Assets0.110.150.14
Total Assets1.523.974.32
Current Liabilities2.422.703.44
Total Liabilities22.0033.1436.96
Total Equity-20.49-29.17-32.64
Cash Flow
Operating Cash Flow-0.34-1.24-0.12
Net Change in Cash-0.401.70-0.68
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2016-4.28------
2017-4.44------
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
20/10/2016PurchaseMr. John Johnston96.0037,50036,000.00
19/10/2016PurchaseMr. John Johnston98.0037,50036,750.00

Company Profile

MaxCyte Inc is a developer and supplier of electroporation technology and instrumentation to biotechnology and pharmaceutical companies engaged in drug discovery, cell therapy and development, biomanufacturing, gene editing and immuno-oncology.
 

Sector

Diagnostics & Research

Market Position

1033 of 1865 Companies

Index

Outlook

(27/09/2016) ceo - "We continue to look forward to the future with great confidence and to building value for our shareholders"

Next Event 31/12/2016

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)0.0013.1215.86
Div Yld (E)0.004.254.26
PEG (E)0.000.200.15
ROCE1.65209.39-30.49
Op Mrgn-7.67-16.09-33.54
EPS Grwth0.0010.0923.13
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. J. Thompson
Chief Financial Officer & Company SecretMr. Ron Holtz
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.